These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1069 related items for PubMed ID: 6601174

  • 1. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.
    Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA.
    J Exp Med; 1983 Mar 01; 157(3):884-97. PubMed ID: 6601174
    [Abstract] [Full Text] [Related]

  • 2. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
    Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA.
    J Exp Med; 1982 Jun 01; 155(6):1823-41. PubMed ID: 6176669
    [Abstract] [Full Text] [Related]

  • 3. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T, Belfrage H, Bhiladvala P, Hedlund G.
    J Immunol; 1987 Jun 01; 138(11):3640-5. PubMed ID: 3495566
    [Abstract] [Full Text] [Related]

  • 4. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL, Herberman RB, Olszowy MW, Cramer DV, Salup RR, Reynolds CW, Hiserodt JC.
    Cancer Res; 1988 Feb 15; 48(4):884-90. PubMed ID: 3257412
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Lymphokine-activated killer (LAK) cells. II. Delineation of distinct murine LAK-precursor subpopulations.
    Ballas ZK, Rasmussen W, van Otegham JK.
    J Immunol; 1987 Mar 01; 138(5):1647-52. PubMed ID: 2879870
    [Abstract] [Full Text] [Related]

  • 7. Suppression of alloimmune cytotoxic T lymphocyte (CTL) generation by depletion of NK cells and restoration by interferon and/or interleukin 2.
    Suzuki R, Suzuki S, Ebina N, Kumagai K.
    J Immunol; 1985 Apr 01; 134(4):2139-48. PubMed ID: 2579129
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Leu-Leu-OMe sensitivity of human activated killer cells: delineation of a distinct class of cytotoxic T lymphocytes capable of lysing tumor targets.
    Thiele DL, Lipsky PE.
    J Immunol; 1986 Aug 15; 137(4):1399-406. PubMed ID: 3488348
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A novel 120-kD surface antigen expressed by a subset of human lymphocytes. Evidence that lymphokine-activated killer cells express this molecule and use it in their effector function.
    Zocchi MR, Bottino C, Ferrini S, Moretta L, Moretta A.
    J Exp Med; 1987 Aug 01; 166(2):319-26. PubMed ID: 3598463
    [Abstract] [Full Text] [Related]

  • 15. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG, Abraham SR, Owen-Schaub LB, Hemingway LL, Hemstreet GP, DeBault LE.
    Cancer Res; 1988 Apr 15; 48(8):2184-92. PubMed ID: 3258186
    [Abstract] [Full Text] [Related]

  • 16. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells.
    Yang JC, Mulé JJ, Rosenberg SA.
    J Immunol; 1986 Jul 15; 137(2):715-22. PubMed ID: 2873187
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires.
    Fox BA, Rosenberg SA.
    Cancer Immunol Immunother; 1989 Jul 15; 29(3):155-66. PubMed ID: 2786456
    [Abstract] [Full Text] [Related]

  • 20. Glycoproteic nature of surface molecules of effector cells with lymphokine-activated killer (LAK) activity. Evidence that T11, T8 or T3 molecules are not involved in tumor-cell lysis by LAK effector T cells.
    Bagnasco M, Mingari MC, Pende D, Venuti D, Canonica GW, Moretta L.
    Int J Cancer; 1987 Jun 15; 39(6):703-7. PubMed ID: 3108168
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.